This trial is active, not recruiting.

Condition thoracic neoplasms
Treatment thoracic 3-d conformal radiotherapy
Sponsor Shanghai Cancer Hospital, China
Start date January 2002
End date January 2006
Trial size 140 participants
Trial identifier NCT00631839, FDCA002


The purpose of this study is to evaluate clinical, dosimetrical, functional, biological and genetic factors in predicting chemo-radiotherapy induced lung and esophagus injury.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
There is only one group in this study. The patients of this group will go through procedures as follow: basic pre-treatment information collected,treatment include platinum-based chemotherapy and 3-D conformal radiotherapy, blood test during RT 6am every Monday and follow-up visits with treatment-induced injury assessed.
thoracic 3-d conformal radiotherapy Thoracic Radiotherapy(TRT)
Thoracic RT tailored for each patient, about 60Gy (NSCLC) or 55Gy (SCLC) with photon energies >=6MV.

Primary Outcomes

Chemo-Radiotherapy induced pneumonitis,fibrosis and esophagus injury assessed with common toxicity criteria adverse effect version3.0 [CTCAE-3.0]
time frame: from the begining of treatment to the end of follow-up

Eligibility Criteria

Male or female participants from 18 years up to 75 years old.

Inclusion Criteria: - Non-pregnant adults (18<= age <= 75 y/o) - Chinese ethnicity - Pathological or cytological proven thoracic neoplasms (of note,sputum cytology alone is not acceptable.Cytological specimens obtained by brushing,washing and needle aspiration of a defined lesion are acceptable) - Initially treated - No distant metastasis - ECOG PS 0-2 (Karnofsky>60%) - Understand and willing to sign the consent - Normal organ and marrow function as defined below: - Leukocytes >=3,000/µL - Haemoglobin >=9 g/dL (prior to transfusions) - Absolute neutrophil count >=1,500/µL - Platelets >=100,000/µL - Total bilirubin < 1.5 x upper limit of normal - AST (SGOT)/ALT (SGPT) ≤2.5 X institutional upper limit of normal - Creatinine <=2.5 mg/dl. Exclusion Criteria: - Prior thoracic radiotherapy - Distant metastasis - Allergic reactions attributed to compounds of similar chemical or biologic composition to platinum-based drugs. - Pre-existed non-oncological pulmonary or esophageal disease that may put the patient at high risk of severe toxicities. - Other uncontrolled intercurrent illness including, but not limited to, ongoing or active infection and psychiatric illness/social situations that would limit compliance with study requirement - pregnancy or lactating - Receiving other investigational agents or devices

Additional Information

Official title Prospect Study to Evaluate Clinical, Dosimetrical, Functional, Biological and Genetic Factors in Predicting Chemo-Radiotherapy Induced Lung and Esophagus Injury
Principal investigator Min Fan, MD
Description We propose a prospective study to investigate the combinational effect of radiotherapeutic dosimetric parameters [mean lung dose and percentage of lung volume receiving at least XGy (Vx)] and biological parameters [interleukin-1α(IL1α),interleukin-1β(IL1β),interleukin-6(IL6),interleukin-7(IL7),transforming growth factor beta (TGFB)] and manganese superoxide dismutase(MnSOD) in predicting radiation pneumonitis, fibrosis, and radiation esophageal injury. Eligibility included pathological or cytological proven thoracic cancer,ECOG performance status [PS] 0-2, no prior thoracic RT or chemotherapy,no distant metastasis and signed informed consent prior to study entry. Basic pre-treatment information will be collected, which included ECOG PS, UICC/AJCC stage,primary lesion site, history of smoking/coexisting lung disease/surgical resection, and pulmonary function test of FEV1/VC/DLCO. Computed tomography [CT] of the whole lung in treatment position. Blood test of IL1α,IL1β,IL6,IL7,TGFB and MnSOD by ELISA will be done before and weekly during RT. RT must be given by photon energies >=6MV. Radiation lung and esophageal injury will be assessed according to common toxicity criteria adverse effect version3.0 [CTCAE-3.0] during RT and in every follow up visits. Genomic DNA is obtained from the blood drawn during RT. Chi-square test, T test, analysis of variance, logistic regression, and proportional hazard ratio method will be used to investigate whether the parameter(s) can be effective in predicting radiation related sequelae.
Trial information was received from ClinicalTrials.gov and was last updated in October 2008.
Information provided to ClinicalTrials.gov by Shanghai Cancer Hospital, China.